ArticleScientific reports2025
Prognostic potential of neutrophil-to-lymphocyte ratio for adverse outcomes in dilated cardiomyopathy: a retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic value of 9 immune-inflammatory markers for patients with dilated cardiomyopathy: A retrospective study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Predictive value of the combined evaluation of the neutrophil-to-lymphocyte ratio and lactate dehydrogenase level for coronary artery lesions in patients with acute Kawasaki disease.Italian journal of pediatrics · 2025Article
- Bridging Gaps in Heart Failure Science: Toward a More Integrated Future.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neutrophil-to-lymphocyte ratio (NLR), as a novel inflammatory marker, has been shown to be associated with the severity and prognosis of various cardiovascular diseases. The aim of this study was to investigate whether NLR can serve as a biomarker for adverse outcomes and prognostic value in patients with dilated cardiomyopathy (DCM). This was a retrospective analysis of 666 consecutive patients with DCM who were admitted to our center for the first time. We compared the NLR levels among different outcome groups and assessed the survival status of patients in different NLR categories. Additionally, we explored the temporal changes in the predictive performance of NLR over time. Cox regression analysis was used to assess the relationship between NLR and prognosis, and subgroup analysis was performed. Furthermore, we investigated the dose-response relationship between NLR and prognosis. A total of 221 patients experienced all-cause death, and the NLR value in the death group (4.6 ± 5.3) was significantly higher than that in the survival group (3.2 ± 2.9) (P < 0.05). In terms of all-cause death, cardiac death, and heart failure death, the cumulative hazard were significantly higher in the NLR ≥ 3 group compared to the NLR < 3 group (P < 0.001). NLR showed a high accuracy in predicting these outcomes, but decreased over time. The results of the multivariable Cox regression analysis demonstrated that NLR was independently associated with all-cause death, cardiac death, and heart failure death (P < 0.05). Higher NLR values were associated with an increased risk of death, while there was no significant correlation with sudden death. In the fully adjusted model, each increase of 1 or 1 standard deviation (SD) in NLR corresponded to a 5% and 20% increase in the risk of all-cause death, a 4% and 15% increase in the risk of cardiac death, and a 5% and 21% increase in the risk of heart failure death (P < 0.05). In the fully adjusted model with all-cause death as the outcome, there was an interaction between NLR and age (P = 0.023), and the elderly population at higher risk. For cardiac death and heart failure death, there was an interaction between NLR and LVEF (P < 0.05), with the subgroup of LVEF < 35% being at higher risk. The relationship between log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.